Mucosal Melanoma Clinical Trial
Official title:
A Phase II Study of Neoadjuvant Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
This study is a randomized ,single center clinical study which is designed to investigate whether combination of Pembrolizumab with Lenvatinib could improve pCR rate and consequent survival in resectable mucosal melanoma. All the eligible patients were assigned to receive Lenvatinib once a day (QD) for 6 weeks plus pembrolizumab on Day 1 of each 21-day cycle (Q3W) concurrently on days 1 and 22, followed by surgery and 18 cycles of Pembrolizumab 200mg q3w of adjuvant phase.
Mucosal melanoma is a rare type of melanoma in Caucasian population and a dominate subtype in Asia, which generally carries a worse prognosis than cutaneous melanoma. Surgery remains the primary therapeutic intervention for mucosal melanoma, and neoadjuvant therapy is still needed which can lead to improvements in outcomes by surgical resectability, local control and organ preservation. Immunotherapy has showed promising activity in advanced melanoma. However, PD-1 antibodies, both Pembrolizumab and Nivolumab, showed much poorer response to mucosal melanoma than to cutaneous melanoma. Pembrolizumab showed modest objective response rate (ORR, 13%) in advanced mucosal melanoma in Chinese population (NCT02628067). Recent study also demonstrated that neoadjuvant therapy with one dose of Pembrolizumab could lead to pathological complete response (pCR) or major response in nearly 30% of resectable advanced melanoma and pCR was associated with reduced risk of recurrence and improved survival. Lenvatinib is also a kinase inhibitor that inhibits the kinase activities of VEGFR1,2, 3 which has been approved by FDA for differentiated thyroid cancer, advanced renal cell carcinoma and hepatocellular carcinoma. It is hypothesized that neoadjuvant Pembrolizumab in combination with Lenvatinib could result in higher anti-tumor activity with lower toxicity and prolong RFS and OS in high-risk resectable mucosal melanoma. The study will assess the efficacy and safety of the combination Pembrolizumab and Lenvatinib as neoadjuvant treatment in resectable mucosal melanoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03241186 -
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
|
Phase 2 | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Active, not recruiting |
NCT03033576 -
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
|
Phase 2 | |
Terminated |
NCT01166126 -
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
Phase 2 | |
Completed |
NCT02158520 -
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 | |
Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT03178123 -
The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT04462965 -
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
|
Phase 2 | |
Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
Not yet recruiting |
NCT06424626 -
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
|
Phase 1 | |
Completed |
NCT00085189 -
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
|
Phase 2 | |
Recruiting |
NCT05384496 -
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
|
Phase 2 | |
Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
Completed |
NCT02126579 -
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05545969 -
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
|
Phase 2 | |
Recruiting |
NCT03986515 -
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
|
Phase 2 |